LEXARIA BIOSCIENCE CORP (LEXX)

Company Profile

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. The company is headquartered in Kelowna, British Columbia and currently employs 5 full-time employees. The company went IPO on 2009-10-28. The firm is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The firm has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. The company operates through two segments: Intellectual Property and Products. The company also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Company Info

LEXARIA BIOSCIENCE CORP

100 - 740 Mccurdy Road

Kelowna BRITISH COLUMBIA V1X 2P7

P: 12507656424

CEO: Christopher Bunka

Employees: 5

Website: https://www.lexariabioscience.com/